Lyme vaccine: issues and controversies (Q34218577)

31 July 2017

1 reference

title

Lyme vaccine: issues and controversies (English)

1 reference

31 July 2017

0 references

Rahn DW

1

1 reference

31 July 2017

language of work or name

1 reference

1 March 2001

1 reference

Infectious Disease Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

15

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

171-187

1 reference

Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Epidemiologic and diagnostic studies of patients with suspected early Lyme disease, Missouri, 1990-1993.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Western blotting in the serodiagnosis of Lyme disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Solitary erythema migrans in Georgia and South Carolina.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Protection of mice against the Lyme disease agent by immunizing with recombinant OspA

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease?

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Lyme borreliosis: relation of its causative agent to its vectors and hosts in North America and Europe

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Chronic neurologic manifestations of Lyme disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The cost effectiveness of vaccinating against Lyme disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Comparison of Cefuroxime Axetil and Doxycycline in the Treatment of Early Lyme Disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

1 reference

7 January 2021

Detection of Borrelia burgdorferi DNA by Polymerase Chain Reaction in Synovial Fluid from Patients with Lyme Arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Culture-Confirmed Infection and Reinfection with Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Induction of an outer surface protein on Borrelia burgdorferi during tick feeding

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Long-term Outcomes of Persons With Lyme Disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Musculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

1 reference

7 January 2021

Treatment of lyme arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

The clinical evolution of Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Efficacy of human Lyme disease vaccine formulations in a mouse model

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(05)70274-9

7 January 2021

10.1016/S0891-5520(05)70274-9

Identifiers

DOI

1 reference

31 July 2017

1 reference